Block, Matthew S https://orcid.org/0000-0001-5692-4219
Nelson, Garth D https://orcid.org/0009-0002-0709-1155
Chen, Jun https://orcid.org/0000-0002-1273-5624
Johnson, Stephen https://orcid.org/0000-0003-0685-9863
Yang, Lu https://orcid.org/0000-0002-5234-3190
Flotte, Thomas James https://orcid.org/0000-0001-5691-8249
Grewal, Eric P https://orcid.org/0000-0002-2189-7975
McWilliams, Robert R https://orcid.org/0000-0002-8199-5040
Kottschade, Lisa A https://orcid.org/0000-0001-8922-2619
Domingo-Musibay, Evidio https://orcid.org/0000-0002-2082-554X
Markovic, Svetomir N https://orcid.org/0000-0002-9238-4325
Dimou, Anastasios https://orcid.org/0000-0002-3950-3305
Montane, Heather N https://orcid.org/0000-0001-7488-4767
Piltin, Mara A https://orcid.org/0000-0002-0863-8258
Price, Daniel L https://orcid.org/0000-0003-3398-0562
Khariwala, Samir S https://orcid.org/0000-0002-5579-4990
Hui, Jane Yuet Ching https://orcid.org/0000-0002-2628-0720
Erskine, Courtney L https://orcid.org/0000-0001-8873-1542
Strand, Carrie A https://orcid.org/0000-0001-7820-6138
Zahrieh, David https://orcid.org/0000-0003-0529-5146
Dong, Haidong https://orcid.org/0000-0002-5782-2983
Hieken, Tina J https://orcid.org/0000-0002-4277-8692
Clinical trials referenced in this document:
Documents that mention this clinical trial
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
https://doi.org/10.1136/jitc-2025-011706
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
https://doi.org/10.1136/jitc-2025-011706
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
https://doi.org/10.1136/jitc-2025-011706
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Funding for this research was provided by:
Stand Up to Cancer-Genentech Catalyst Research Grant Award administered by the American Association for Cancer Research (SU2C-AACR-CT1017)
Mayo Clinic Center for Clinical and Translational Science (Award 92541640-2020/Mayo Clinic)